Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.56 |
| ▸ | PI4KA | P42356 | 8/20 | 0.53 |
| ▸ | PI4K2B | Q8TCG2 | 8/20 | 0.53 |
| ▸ | PI4K2A | Q9BTU6 | 8/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 8/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30962317 | 1.00 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL42314 | 0.79 | ADORA2A (0.66) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL29400753 | 0.79 | ADORA2A (0.66) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL1059581 | 0.78 | NUDT1 (0.68) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL30109321 | 0.78 | NUDT1 (0.68) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL8566 | 0.76 | ADORA2A (1.00) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL843169 | 0.76 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL42335 | 0.76 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL31096978 | 0.76 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL842891 | 0.76 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257360-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | UNIV OKLAHOMA (US) | 2025-08-14 | — | — | US | claimed |
| CN-113151261-B | Antisense oligonucleotides as inhibitors of TGF-R signaling | 神经视觉医药有限公司 | 2025-06-17 | — | — | CN | claimed |
| EP-4504945-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | The Board of Regents of the University of Oklahoma (US) | 2025-02-12 | — | — | EP | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20240294924-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-09-05 | — | — | US | claimed |
| CN-117795071-A | Antisense oligonucleotides for preventing renal dysfunction caused by endothelial dysfunction through inhibition of ephrin-B2 | 马克斯·普朗克科学促进学会 | 2024-03-29 | — | — | CN | claimed |
| EP-4330397-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-03-06 | — | — | EP | claimed |
| WO-2023196944-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2022263569-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-22 | — | — | WO | claimed |
| EP-4105328-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-21 | — | — | EP | claimed |
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-10-16 | — | — | US | claimed |
| EP-1295891-A1 | NUCLEOSIDE DERIVATIVES | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | claimed |
| US-20030054410-A1 | Combinatorial protecting group strategy for multifunctional molecules | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-03-20 | — | — | US | claimed |
| US-6528639-B2 | Active ribozyme | RIBOZYME PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | claimed |
| US-5891684-A | RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | claimed |
| EP-0898575-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KÖSTER, Hubert (US) | 1999-03-03 | — | — | EP | claimed |
| WO-1997041139-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT (US) | 1997-11-06 | — | — | WO | claimed |
| US-5665541-A | Formation of triple helix complexes for the detection of double stranded DNA sequences using oligomers which comprise an 8-modified purine base | THE JOHNS HOPKINS UNIVERSITY (US) | 1997-09-09 | — | — | US | claimed |
| EP-0672171-A1 | FORMATION OF TRIPLE HELIX COMPLEXES OF DOUBLE STRANDED DNA USING NUCLEOSIDE OLIGOMERS WHICH COMPRISE PURINE BASE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-09-20 | — | — | EP | claimed |
| WO-1993005180-A1 | FORMATION OF TRIPLE HELIX COMPLEXES OF DOUBLE STRANDED DNA USING NUCLEOSIDE OLIGOMERS WHICH COMPRISE PURINE BASE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 1993-03-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | ADAR, RNMT, ATIC | ADORA2A 113/4885ADORA1 242/4885NUDT1 264/4885 |
| US-20030054410-A1 | Combinatorial protecting group strategy for multifunctional molecules | ADAR, RNMT, RRM1 | ADORA2A 123/4885ADORA1 217/4885NUDT1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.